Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property

Devonian Advances Thykamine(TM) Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls

By The Northwire Desk — AI Analysis Feb 17, 2026 · 09:00 GSD · 14.0 Devonian Health Group Inc.
GSD · Price

Executive Summary

  • Devonian Health Group filed two patent applications covering a proprietary “Thykamine™ fingerprint,” making it a core element of its long‑term IP strategy.
  • The fingerprint defines eight specific chemical components in precise ratios, validated by HPLC‑MS, NMR, and potency assays showing ≥98% batch‑to‑batch consistency.
  • These analytical controls will be incorporated into the Chemistry, Manufacturing & Controls (CMC) framework for Thykamine™ production, bolstering regulatory readiness and product quality assurance.

Key Details

  • Patent Filings: Two recent applications formally disclose the proprietary Thykamine™ fingerprint; the filings are now part of Devonian’s core IP portfolio.
  • Fingerprint Composition: Eight defined chemical components with exact ratios identified via advanced HPLC‑MS methods.
  • Analytical Validation:
  • HPLC‑MS methodology demonstrated high reproducibility across manufactured batches.
  • Independent NMR analysis confirmed ≥98% confidence in batch‑to‑batch consistency.
  • Biological Potency Assays:
  • U‑937 human cell‑based model showed each batch consistently inhibits key inflammatory cytokines (RANTES, MIP‑1β).
  • Assays are being validated for inclusion in the CMC section of Thykamine™ production dossiers.
  • Regulatory Impact: The combined chemical fingerprinting, NMR confirmation, and potency data will form an integral part of Devonian’s CMC framework, supporting future regulatory submissions.
  • CEO Quote: Dr. André Boulet emphasized that the integrated analytical approach ensures every batch of Thykamine™ delivers consistent quality, efficacy, and reliability for patients.

Notable Quotes

“These analytical and biological methods clearly demonstrate the quality and consistency of Thykamine™ produced in every batch— not only from a chemical standpoint, but also as an active anti‑inflammatory and anti‑fibrotic pharmaceutical.” – Dr. André Boulet, CEO, Devonian Health Group Inc.

Read the original news release →

More from Devonian Health Group Inc.

Jun 29, 2026 · 20:00

Devonian's cash runway narrows to months as Altius revenue vanishes and pipeline remains pre-revenue

Earnings Mar 25, 2026 · 16:22

Devonian Health Faces Liquidity Cliff as Distribution Revenue Dries Up and Biotech Pivot Demands Fresh Capital

Earnings Feb 19, 2026 · 09:00

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine(TM), with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Other Feb 12, 2026 · 19:58

Devonian preclinical data support Thykamine

Other Feb 12, 2026 · 09:00

Devonian reports additional molecular data from MASH liver study

Other Feb 10, 2026 · 09:00

DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY

Other